TY - JOUR
T1 - Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy
AU - Guan, Xiaoxiang
AU - Yin, Ming
AU - Wei, Qingyi
AU - Zhao, Hui
AU - Liu, Zhensheng
AU - Wang, Li E.
AU - Yuan, Xianglin
AU - O'Reilly, Michael S.
AU - Komaki, Ritsuko
AU - Liao, Zhongxing
N1 - Funding Information:
We thank Jiangong Niu, Jianzhong He and Kejing Xu and for their technical assistance. This study was in part supported by National Institutes of Health grants R01 ES11740 and R01 CA 131274 (to Q. W.) and P30 CA 16672 (to M. D. Anderson Cancer Center).
PY - 2010/8/16
Y1 - 2010/8/16
N2 - Background: Vascular endothelial growth factor (VEGF) is a major mediator of angiogenesis involving in carcinogenesis, including lung cancer. We hypothesized that VEGF polymorphisms may affect survival outcomes among locally advanced non-small cell lung cancer (LA-NSCLC) patients.Methods: We genotyped three potentially functional VEGF variants [-460 T > C (rs833061), -634 G > C (rs2010963), and +936 C > T (rs3025039)] and estimated haplotypes in 124 Caucasian patients with LA-NSCLC treated with definitive radiotherapy. We used Kaplan-Meier log-rank tests, and Cox proportional hazard models to evaluate the association between VEGF variants and overall survival (OS).Results: Gender, Karnofsky's performance scores (KPS) and clinical stage seemed to influence the OS. The variant C genotypes were independently associated with significantly improved OS (CT+CC vs. TT: adjusted hazard ratio [HR] = 0.58; 95% confidence interval [CI] = 0.37-0.92, P = 0.022), compared with the VEGF -460 TT genotype.Conclusions: Our study suggests that VEGF -460 C genotypes may be associated with a better survival of LA-NSCLC patients after chemoradiotherapy. Large studies are needed to confirm our findings.
AB - Background: Vascular endothelial growth factor (VEGF) is a major mediator of angiogenesis involving in carcinogenesis, including lung cancer. We hypothesized that VEGF polymorphisms may affect survival outcomes among locally advanced non-small cell lung cancer (LA-NSCLC) patients.Methods: We genotyped three potentially functional VEGF variants [-460 T > C (rs833061), -634 G > C (rs2010963), and +936 C > T (rs3025039)] and estimated haplotypes in 124 Caucasian patients with LA-NSCLC treated with definitive radiotherapy. We used Kaplan-Meier log-rank tests, and Cox proportional hazard models to evaluate the association between VEGF variants and overall survival (OS).Results: Gender, Karnofsky's performance scores (KPS) and clinical stage seemed to influence the OS. The variant C genotypes were independently associated with significantly improved OS (CT+CC vs. TT: adjusted hazard ratio [HR] = 0.58; 95% confidence interval [CI] = 0.37-0.92, P = 0.022), compared with the VEGF -460 TT genotype.Conclusions: Our study suggests that VEGF -460 C genotypes may be associated with a better survival of LA-NSCLC patients after chemoradiotherapy. Large studies are needed to confirm our findings.
UR - http://www.scopus.com/inward/record.url?scp=77955533448&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955533448&partnerID=8YFLogxK
U2 - 10.1186/1471-2407-10-431
DO - 10.1186/1471-2407-10-431
M3 - Article
C2 - 20712888
AN - SCOPUS:77955533448
SN - 1471-2407
VL - 10
JO - BMC cancer
JF - BMC cancer
M1 - 431
ER -